Tesamorelin and Ipamorelin Peptide Blend
Tesamorelin and Ipamorelin Peptide Blend and Lipodystrophy Research
Studies suggest that the Tesamorelin and Ipamorelin blend is composed of two peptides with potential overlapping mechanisms for stimulating the growth hormone axis. Research suggests that this synergistic interaction may stimulate the pituitary gland, producing natural growth hormone.
The blend may elicit possible impacts on sleep, metabolic function, cognition, and lipid profiles, as well as a way to optimize growth hormone levels. [i] [ii]
Tesamorelin and Ipamorelin may have synergistic impacts, as suggested by scientific studies. These impacts may include better deep sleep, decreased triglyceride, VAT, and cIMT levels, improved cognition, and even possible optimization of metabolic function.
This blend looks to provide a chance to use the complementary impact of both ingredients to increase levels of natural growth hormone potentially.
Many hypothesized modes of action may contribute to the synergistic effects of Tesamorelin and Ipamorelin. It seems that Tesamorelin, a GHRH analog, may work by binding to and activating the GHRH receptor on pituitary somatotrophs.
This stimulus may pulsatilely trigger endogenous growth hormone (GH) production and secretion. By stimulating growth hormone production, Tesamorelin may potentially improve glucose metabolism, increase lipolysis, and decrease visceral adipose tissue.
On the other hand, Ipamorelin, a GHSR agonist, seems to activate GHSR in the hypothalamus and peripheral tissues, which may result in the release of GH. Inhibiting GHSR with this peptide may be possible without affecting other hormones due to its apparent strong selectivity for GHSR.
Researchers hypothesize that Ipamorelin may stimulate GH secretion by activating the GH receptor, boosting protein synthesis, fat breakdown, and IGF-1 production.
It has been purported that Tesamorelin and Ipamorelin may target different parts of the growth hormone axis; hence, their combination may synergize. It has been hypothesized that Tesamorelin may improve GHRH-mediated GH secretion, whereas Ipamorelin may increase GH secretion by directly stimulating GHSR.
This synergistic impact seems to magnify the positive outcomes of GH in experimental animals, including enhanced body composition, lipid profile, insulin sensitivity, and metabolic function. Tesamorelin and Ipamorelin seem to target the growth hormone axis differently, and their combined impact on the pituitary gland may increase endogenous growth hormone production. [iii]
The pituitary gland is a key endocrine organ, and it is thought that the Tesamorelin and Ipamorelin combination may affect its growth hormone output.
Researchers speculate that Tesamorelin may stimulate growth hormone production and release by directly binding to and activating the growth hormone-releasing receptor (GHRHR). They implied that "Tesamorelin is a synthetic growth hormone-releasing hormone that acts on the anterior pituitary gland to stimulate the endogenous growth hormone secretion." [iv]
In contrast, Ipamorelin suggests potential as a possible agonist for the growth hormone secretagogue receptor (GHSR), suggesting it may stimulate the production of this hormone. [v] "Ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH," the research suggested. It has been hypothesized that Ipamorelin may be a potential molecule for further experimental research due to its high specificity. [v]
These peptides may stimulate the pituitary gland to produce more growth hormone when working together, research suggests.
In addition to insulin resistance, dyslipidemia, and an increased risk of cardiovascular problems, lipodystrophy is commonly associated with these conditions, as suggested by cumulative research.
Experimental studies on lipodystrophic research models have suggested Tesamorelin's potential to enhance insulin sensitivity and lipid profiles by decreasing visceral adipose tissue (VAT).
Tesamorelin's mechanism of action seems to include activation of the growth hormone-releasing hormone receptor (GHRHR), with the latter having the ability to preserve "abdominal subcutaneous adipose tissue, improving body image and lipids" while the former boosting endogenous growth hormone production and encouraging lipolysis. [vi]
Ipamorelin has also been purported to show the potential to affect fatty tissue metabolism. Researchers suggest that by combining Tesamorelin and Ipamorelin, the synergistic potential of these peptides may increase VAT reduction and improve metabolic parameters in lipodystrophy test mice. [vi]
Data suggests that growth hormone and its secretagogues, like Tesamorelin and Ipamorelin, may contribute to cognitively important processes, including neuroplasticity, neuronal survival, and synaptic plasticity.
Additionally, experimental studies have hypothesized that Tesamorelin's potential impact on neurogenesis and synaptic plasticity may aid memory and learning. Research using animal models suggests that Ipamorelin may improve spatial memory and cognitive performance.
Scientists speculate that this combination may enhance cognition by activating the growth hormone axis and influencing neurotrophic factors.
Tesamorelin and Ipamorelin have suggested promise in experimental investigations to enhance glycemic control and decrease metabolic abnormalities in type 2 diabetes.
Increased insulin sensitivity and glucose utilization have long been thought to result from increased endogenous growth hormone production, which Tesamorelin seems to accomplish. Moreover, Ipamorelin's research suggests the peptide may affect glucose metabolism and insulin sensitivity.
The potential synergistic impact of combining Tesamorelin with Ipamorelin includes, but is not limited to, increases in insulin sensitivity and decreases in visceral adiposity in research models with Type II Diabetes Mellitus. [vii]
Tesamorelin & Ipamorelin blend for sale is available at Core Peptides for scientists interested in further studying the possibly synergistic impact of these compounds.
References
[i] Adrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dubé MP, Stanley T, Grinspoon S, Mamputu JC, Marsolais C, Brown TT, Erlandson KM. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019;8(3):154-159. doi: 10.14283/jfa.2018.45. PMID: 31237318; PMCID: PMC6766405. https://pubmed.ncbi.nlm.nih.gov/31237318/
[ii] Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017 Jun 15;12(6):e0179538. doi: 10.1371/journal.pone.0179538. PMID: 28617838; PMCID: PMC5472315. https://pubmed.ncbi.nlm.nih.gov/28617838/
[iii] Rogério G. Gondo et al, Growth Hormone-Releasing Peptide-2 Stimulates GH Secretion in GH-Deficient Patients with Mutated GH-Releasing Hormone Receptor, The Journal of Clinical Endocrinology & Metabolism, Volume 86, Issue 7, 1 July 2001, Pages 3279–3283, https://doi.org/10.1210/jcem.86.7.7694
[iv] Adrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dubé MP, Stanley T, Grinspoon S, Mamputu JC, Marsolais C, Brown TT, Erlandson KM. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019;8(3):154-159. doi: 10.14283/jfa.2018.45. PMID: 31237318; PMCID: PMC6766405. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766405/
[v] Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
[vi] Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010 Sep;95(9):4291-304. doi: 10.1210/jc.2010-0490. Epub 2010 Jun 16. PMID: 20554713. https://pubmed.ncbi.nlm.nih.gov/20554713
[vii] Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017 Jun 15;12(6):e0179538. doi: 10.1371/journal.pone.0179538. PMID: 28617838; PMCID: PMC5472315. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472315/
Get The CEO Magazine to your Door Steps; Subscribe Now
